BioMaxima SA · GPW:BMX

BioMaxima SA — Wood&Company conference in Prague 2021

22 slides from BioMaxima SA's conference presentation, May 19, 2021

  1. Slide 1: Company Profile May 2021

    C O M PA N Y P R O F I L E M AY 2 0 2 1 L E A D I N G L I FE - S C I E N C E IN P O L A N D

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation was prepared by BioMaxima S.A. in Lublin. Poland („BioMaxima”). The only purpose of this presentation is to provide its user with reliable information regarding the business and financial situation of BioMaxima. It is not aiming to solicit anybody to purchase any securit

  3. Slide 3: Who We Are

    WHO P u re IVD player, with specialization in infectious disease. WE ARE B i o M ax i m a SA i s a E U b ra n d o f fe r i n g c o m p et i t i v e l y p r i c e d s o l u t i o n s fo r l a b o rato r i e s . T h e n e w p r o d u c t s we develop lie w i t h i n o u r p r o p r i e t a r y mature

  4. Slide 4: Over 2000 end-user clients in Poland; distributors in over 60 countries

    Over 2000 end-user clients in Poland (laboratories) Distributors in over 60 countries in Europe,Asia, Africa and Americas, OEM relationships with leading European brands P AT I E N T S PROCESS E N V IR O N ME N TA L M O N I TO R I N G SAMPLES C O N TR O L D IA G N O S T IC S R AW FINISHED MAT E R IA

  5. Slide 5: Key Products Categories

    KEY PRODUCTS Global IVD market is currently worth 83 bilion EUR. The average expenditure in the EU per capita is EUR 20, an d in Polan d it is EUR 9.8, th erefore th ere is sign ificant p otential for c onvergence CATEGORIES growth. Global market FOR DRUG SUSCEPTIBILITY TESTING within IVD will reach

  6. Slide 6: Most dynamically growing life-science company in Poland

    H i g h bar ier of e nt r y for n e w c o m e r s : h i g h c o s t of h u m a n c a p i ta l development, t e c h n o l o g i c a l b a r e e r : off-shelf m a n u f a c t u r i n g e q u i p m e n t n o t available, c lient r e q u r e s w i d e r a n g e of p r o d u c t s p r o v i d e d b y s a

  7. Slide 7: Technology Platforms

    TECHNOLOGY PLATFORMS AST R A P I D TE STS MICROBIOLOGY BIOCHEMISTRY Multiple immunochromatographic tests Solutions for IVD and Instruments and reagents: Antibiotic Susceptibility Testing: industrial market. for infectious diseases (including COVID-19), dedicated and TABLETS, PAPER DISCS, Complete of

  8. Slide 8: COVID Response

    COVID RESPONSE The rise of COVID-19 pandemic was an opportunity for the life-science business. Society, governments and health sector were expecting the industry to provide an adequate and reliable tools to fight the pandemic and protect the people. BioMaxima was among the first to respond to this n

  9. Slide 9: 2020 Revenue Structure

    2020 REVENUE STRUCTURE PLN 65,5 MILLION NET REVENUE PLN 40,5 MILLION REVENUE FROM OWN PRODUCT SALES PLN 19,5 MILLION EXPORT SALES REVENUE OF THE DOMESTIC REVENUE: PLN 12,5 MILLION SALES TO INDUSTRIAL MARKET PLN 33,5 MILLION SALES TO CLINICAL MARKET

  10. Slide 10: Export Markets

    EUROP E 2019 T U R N O V E R P L N 5 062 433 2020 TURN OVER P L N A T L A N T IC 8 989 402 O C EA N PA C IF IC O C EA N A S IA & P A C I F IC PA C IF IC 2019 T U R N O V E R P L N O C EA N 1 74 8 8 54 IN D IA N O C EA N 2020 TURN OVER P L N 2 157 0 8 0 MIDDLE EAST & AFRICA 2019 T U R N O V E R P L N

  11. Slide 11: BioMaxima's Facilities

    O r i g i n a l B i o M a x i m a ’s 1000m2 building 2 0 0 0 m 2 fa c i l i t i e s Existing 1 0 5 0 m 2 building f r o m 2011 c o n s t r u c t e d 2018-2019 o n t h e a c q u i r e d p l o t F r e e s p a c e for c o n s t r u c t i o n of ca. 9 0 0 m 2 production facility o n acquired plot B I O

  12. Slide 12: BioMaxima is predominantly a manufacturer, not a trading company

    BIOMAXIMA IS P R E D O M I N A N T LY A M A N U FA C T U R E R , N O T A T R A D I N G C O M PA N Y. Fully automated production line for antibiotic discs. The line has been designed and manufactured with involvement of BioMaxima engineers and one of BioMaxima’s microbiological media production lines

  13. Slide 13: Company history timeline

    1997 BIOCORP Polska Sp. z 2012 Acquisition of Emapol 2020 Securing of neighbouring real estate for purchase; o.o. established in Warsaw; Sp z o.o. Production of Securing the space for further development of BioMaxima’s Production of microbiological media and production capacity in new facilities mic

  14. Slide 14: Shareholders and Management

    SHAREHO LDERS AND MANAGEMENT Ł Urban 11,89% A Mikosz with TriCar 9.44% M Nowak ŁUKASZ URBAN HENRYK LEWCZUK A N D R Z E J M I KOSZ 4.98% CEO CFO D e p u t y C h a i r m a n of K Mikosz Yale University - MSc - P Z Cormay SA CFO Supervisory Board, 0.49% Molecular Biology ’94 – ’02 A c t i n g M e m b e

  15. Slide 15: Key Financial Figures

    KEY FINANCIAL FIGURES Equity- c o n s e q u e n c e s of I F R S i n t r o d u c t i o n S a l e s 2019-2020 EBITDA N e t P ro f i t

  16. Slide 16: Key Financial Figures 2019-2021: Equity

    K E Y F I N A N C I A L F I G U R E S 2019-2021 30 20 BRIEF MD&A MILLIONS With introduction of the IFRS BioMaxima has adopted new strict Accounting Policy that provides for disciplined valuation of its assets. This Policy has been retroactively used for the preparation of the Historical Financial 10

  17. Slide 17: Key Financial Figures 2019-2021: Sales Revenue

    K E Y F I N A N C I A L F I G U R E S 2019-2021 30 20 BRIEF MD&A Decrease of revenues in 2018 and beginning of 2019 has MILLIONS been reversed with the end of 3rd quarter of 2019. The extensive investment program (construction of new facility in Lublin) and some delays in deliveries of 10 equipment

  18. Slide 18: Key Financial Figures 2019-2021: EBITDA

    K E Y F I N A N C I A L F I G U R E S 2019-2021 20 15 BRIEF MD&A The chart provides information regarding the LTM MILLIONS EBITDA. Since the Company has not been reporting 10 under the IFRS in 2019, the only reliable figures could have been presented since Q1 2020. The EBITDA(LTM) increased in this

  19. Slide 19: Key Financial Figures 2019-2021: Net Profit

    K E Y F I N A N C I A L F I G U R E S 2019-2021 8 6 BRIEF MD&A MILLIONS 4 After negative results in 2018, BioMaxima returned to profit path in 2019. Negative result for 2019 has been caused by recording of the costs of the Management Stock Option Plan. It 2 may be confirmed by slight increase of the

  20. Slide 20: Where Do We Go Next? Post-covid

    W H E R E DO W E GO NEXT? Post-covid

  21. Slide 21: Growth strategy: own products, export team, solar power

    In order to maintain high profitability and high E B I T D A margin, BioMaxima will increase share of its own products in its portfolio. The production and storage of microbiological media as well as lyophilisation process are energy extensive. In order to mitigate the increased energy prices BioMax

  22. Slide 22: Thank You

    THANK YOU FOR YOUR T I M E AND ATTENTION ŁUKASZ URBAN A N D R Z E J MIKOSZ E-MAIL ADDRES [email protected]

BioMaxima — Wood&Company conference in Prague 2021 on 6ix